SLNO - Soleno Therapeutics, Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$53.00
DETAILS
HIGH:
$53.00
LOW:
$53.00
MEDIAN:
$53.00
CONSENSUS:
$53.00
DOWNSIDE:
0.02%
About Soleno Therapeutics, Inc. (https://soleno.life)
Soleno Therapeutics, Inc. (SLNO) operates as a clinical-stage biopharmaceutical company, specializing in the creation and market introduction of groundbreaking treatments for uncommon illnesses. The cornerstone of its therapeutic pipeline is Diazoxide Choline Controlled-Release, a once-daily oral tablet aimed at addressing Prader-Willi Syndrome, currently progressing through an active Phase III clinical evaluation. Established in 1999, the Redwood City, California-headquartered firm adopted its current name, Soleno Therapeutics, Inc., in May 2017, having previously operated as Capnia, Inc.
Key Executives
| NAME | TITLE | DOB | SALARY |
|---|---|---|---|
| Anish Bhatnagar | Chairman, President & CEO | 1970 | $1,230,740 USD |
| James H. MacKaness | Executive Officer | 1964 | $734,908 USD |
| Meredith Manning | Chief Commercial Officer | 1972 | $676,588 USD |
| Jennifer Fulk | Chief Financial Officer | 1977 | $640,000 USD |
| Patricia C. Hirano | Senior Vice President of Regulatory Affairs | 1966 | $515,813 USD |
| Manher A. Joshi | Chief Development Officer | 1968 | $514,721 USD |
| Kevin Norrett | Chief Business Officer | 1973 | $487,331 USD |
| Kristen Yen | Senior Vice President of Global Clinical Operations and Patient Advocacy | 1969 | $317,190 USD |
| Dairine Dempsey | Senior Vice President of Europe | – | – |
| Jesse Schumaker | General Counsel | – | – |
| Lauren Budesheim | Senior Vice President of People | – | – |
| Michael Huang | Senior Vice President of Clinical Development | 1974 | – |
| Mitchell Nagao | Senior Vice President of Medical Affairs | – | – |
| Neil Cowen | Senior Vice President of New Product Planning | – | – |